| Literature DB >> 29867593 |
Xiuhua Li1, Fengjiao Ding2, Pandeng Luo2, Jing Yang3, Zhenhua Liu4, Jinwei Liu5, Yali Zhang1, Aimin Leng6, Kuangming Wu1.
Abstract
OBJECTIVE: To assess the correlation between the incidence of non-erosive reflux disease (NERD) and mental and psychological factors, deepen the understanding of the pathogenesis of NERD and explore effective treatments.Entities:
Keywords: anxiety; cognitive-behavioral therapy; depression; drug therapy; non-erosive reflux disease
Year: 2018 PMID: 29867593 PMCID: PMC5954135 DOI: 10.3389/fpsyt.2018.00115
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Comparison of HAMD scores before and after treatment in each group.
| Drug treatment group | Psychotherapy group | Psychotherapy combined with drug treatment group | η2 | ||
|---|---|---|---|---|---|
| Pretreatment | 14.26 ± 3.721 | 14.03 ± 2.948 | 14.63 ± 4.068 | 0.281 | 0.003 |
| After 4 weeks | 14.29 ± 3.304 | 13.85 ± 2.607 | 10.13 ± 2.747 | 24.438 | 0.180 |
| After 8 weeks | 14.11 ± 3.954 | 10.55 ± 3.419 | 8.98 ± 2.281 | 24.052 | 0.178 |
| After 12 weeks | 14.03 ± 3.981 | 8.28 ± 3.302 | 6.63 ± 2.579 | 51.787 | 0.318 |
*P<0.05.
**P<0.01.
Comparison of HAMA scores before and after treatment in each group.
| Drug treatment group | Psychotherapy group | Psychotherapy combined with drug treatment group | η2 | ||
|---|---|---|---|---|---|
| Pretreatment | 15.29 ± 3.383 | 14.98 ± 3.893 | 15.23 ± 4.098 | 0.072 | 0.001 |
| After 4 weeks | 15.17 ± 4.376 | 14.75 ± 4.634 | 11.13 ± 3.688 | 10.660 | 0.088 |
| After 8 weeks | 14.86 ± 3.942 | 11.25 ± 3.418 | 7.18 ± 2.459 | 50.872 | 0.314 |
| After 12 weeks | 15.11 ± 4.013 | 7.85 ± 3.294 | 4.75 ± 2.048 | 102.89 | 0.481 |
*P<0.05.
**P<0.01.
Figure 1Comparison of HAMD scores before and after treatment in each group.
Figure 2Comparison of HAM scores before and after treatment in each group.
Comparison of symptom scores before and after treatment of patients in each group.
| Drug treatment group | Psychotherapy group | Psychotherapy combined with drug treatment group | η2 | ||
|---|---|---|---|---|---|
| Pretreatment | 22.26 ± 9.516 | 22.78 ± 9.744 | 22.08 ± 7.934 | 0.064 | 0.001 |
| After 4 weeks | 17.51 ± 6.840 | 21.00 ± 6.013 | 15.35 ± 5.066 | 9.083 | 0.076 |
| After 8 weeks | 14.97 ± 5.732 | 16.73 ± 6.425 | 10.50 ± 3.602 | 14.203 | 0.113 |
| After 12 weeks | 8.86 ± 3.836 | 10.60 ± 3.855 | 6.45 ± 2.521 | 14.641 | 0.117 |
*P < 0.05.
**P < 0.01.
Figure 3Comparison of symptom scores before and after treatment of patients in each group.
Comparison of SF-36 scores before and after treatment (M ± SD).
| Drug treatment group | Psychotherapy group | Psychotherapy combined with drug treatment group | ||||
|---|---|---|---|---|---|---|
| Pretreatment | After 12 weeks | Pretreatment | After 12 weeks | Pretreatment | After 12 weeks | |
| Physical functioning | 84.03 ± 7.46 | 87.74 ± 6.31a | 84.28 ± 7.29 | 85.63 ± 7.76b | 83.10 ± 9.06 | 91.90 ± 6.24a,b,c |
| Role-physical | 50.49 ± 7.13 | 55.63 ± 8.89a | 50.00 ± 18.15 | 52.93 ± 15.91 | 50.83 ± 22.56 | 63.00 ± 20.01a,c |
| Bodily pain | 61.94 ± 8.44 | 67.00 ± 6.88a | 61.90 ± 20.44 | 64.00 ± 21.59 | 64.68 ± 22.41 | 77.00 ± 15.97a,b,c |
| General health | 70.74 ± 8.12 | 75.89 ± 8.72a | 71.60 ± 17.58 | 79.90 ± 15.76a | 71.35 ± 19.05 | 84.10 ± 16.38a,b |
| Vitality | 56.14 ± 19.14 | 62.2 ± 19.22a | 55.93 ± 20.36 | 63.10 ± 21.99a | 55.95 ± 21.72 | 74.28 ± 18.11a,b,c |
| SF | 70.60 ± 20.13 | 78.6 ± 18.69a | 70.50 ± 19.18 | 80.83 ± 14.99a | 72.85 ± 17.68 | 87.83 ± 13.48a,b |
| RE | 51.97 ± 26.07 | 57.4 ± 23.95a | 51.58 ± 20.21 | 64.03 ± 21.72a | 50.58 ± 22.44 | 73.08 ± 21.18a,b |
| Mental health | 60.40 ± 15.37 | 66.7 ± 20.21a | 60.63 ± 18.68 | 73.30 ± 12.28a | 61.08 ± 18.34 | 76.93 ± 14.05a,b |
Compared with prior treatment, .
Effects of 12 weeks of treatment in each group.
| Cases | Validity (%) | Invalidity (%) | |
|---|---|---|---|
| Drug treatment group | 35 | 26 (74.29) | 9 (25.71) |
| Psychotherapy group | 40 | 23 (57.5) | 17 (42.5) |
| Psychotherapy combined with drug treatment group | 40 | 38 (95) | 2 (5) |